Since EGFR was found to be over-expressed in a number of cancer cell lines, including those from breast, colon, non-small cell lung, renal, melanoma, ovarian, and prostate cancers we selected EGFR as a potential target and the mechanism behind the anticancer activity of the title compounds. The gene discussed is EGFR; the disease is prostate cancer.